Testing effectiveness (Phase 2)Study completedNCT00630110
What this trial is testing
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Who this might be right for
Cancer
Nereus Pharmaceuticals, Inc. 172